150 related articles for article (PubMed ID: 32388444)
1. Dosimetric predictors of patient-reported toxicity after prostate stereotactic body radiotherapy: Analysis of full range of the dose-volume histogram using ensemble machine learning.
Pan X; Levin-Epstein R; Huang J; Ruan D; King CR; Kishan AU; Steinberg ML; Qi XS
Radiother Oncol; 2020 Jul; 148():181-188. PubMed ID: 32388444
[TBL] [Abstract][Full Text] [Related]
2. Plan quality and dosimetric association of patient-reported rectal and urinary toxicities for prostate stereotactic body radiotherapy.
Qi XS; Wang JP; Gomez CL; Shao W; Xu X; King C; Low DA; Steinberg M; Kupelian P
Radiother Oncol; 2016 Oct; 121(1):113-117. PubMed ID: 27587270
[TBL] [Abstract][Full Text] [Related]
3. Dosimetric predictors for genitourinary toxicity in MR-guided stereotactic body radiation therapy (SBRT): Substructure with fraction-wise analysis.
Pham J; Neilsen BK; Liu H; Cao M; Yang Y; Sheng K; Ma TM; Kishan AU; Ruan D
Med Phys; 2024 Jan; 51(1):612-621. PubMed ID: 38055353
[TBL] [Abstract][Full Text] [Related]
4. An Investigation of Dosimetric Correlates of Acute Toxicity in Prostate Stereotactic Body Radiotherapy: Dose to Urinary Trigone is Associated with Acute Urinary Toxicity.
Henderson DR; Murray JR; Gulliford SL; Tree AC; Harrington KJ; Van As NJ
Clin Oncol (R Coll Radiol); 2018 Sep; 30(9):539-547. PubMed ID: 29807801
[TBL] [Abstract][Full Text] [Related]
5. Dosimetric predictors of acute bowel toxicity after Stereotactic Body Radiotherapy (SBRT) in the definitive treatment of localized prostate cancer.
Repka MC; Carrasquilla M; Paydar I; Wu B; Lei S; Suy S; Collins SP; Kole TP
Acta Oncol; 2023 Feb; 62(2):174-179. PubMed ID: 36826994
[TBL] [Abstract][Full Text] [Related]
6. Dosimetric parameters predict short-term quality-of-life outcomes for patients receiving stereotactic body radiation therapy for prostate cancer.
Gomez CL; Xu X; Qi XS; Wang PC; Kupelian P; Steinberg M; King CR
Pract Radiat Oncol; 2015; 5(4):257-62. PubMed ID: 25749214
[TBL] [Abstract][Full Text] [Related]
7. Rectal spacer hydrogel in 1.5T MR-guided and daily adapted SBRT for prostate cancer: dosimetric analysis and preliminary patient-reported outcomes.
Alongi F; Rigo M; Figlia V; Cuccia F; Giaj-Levra N; Nicosia L; Ricchetti F; Vitale C; Sicignano G; De Simone A; Naccarato S; Ruggieri R; Mazzola R
Br J Radiol; 2021 Jan; 94(1117):20200848. PubMed ID: 33095659
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Monte Carlo algorithm for compliance with RTOG 0915 dosimetric criteria in peripheral lung cancer patients treated with stereotactic body radiotherapy.
Pokhrel D; Sood S; Badkul R; Jiang H; McClinton C; Lominska C; Kumar P; Wang F
J Appl Clin Med Phys; 2016 May; 17(3):277-293. PubMed ID: 27167284
[TBL] [Abstract][Full Text] [Related]
9. Patient and Dosimetric Predictors of Genitourinary and Bowel Quality of Life After Prostate SBRT: Secondary Analysis of a Multi-institutional Trial.
Wang K; Chen RC; Kane BL; Medbery CA; Underhill KJ; Gray JR; Peddada AV; Fuller DB
Int J Radiat Oncol Biol Phys; 2018 Dec; 102(5):1430-1437. PubMed ID: 30056080
[TBL] [Abstract][Full Text] [Related]
10. Early Exploratory Analysis for Patient-reported Quality of Life and Dosimetric Correlates in Hypofractionated Stereotactic Body Radiation Therapy (SBRT) for Low-risk and Intermediate-risk Prostate Cancer: Interim Results from a Prospective Phase II Clinical Trial.
Iarrobino NA; Gill B; Sutera PA; Kalash R; D' Ambrosio D; Heron DE
Am J Clin Oncol; 2019 Nov; 42(11):856-861. PubMed ID: 31584457
[TBL] [Abstract][Full Text] [Related]
11. Development and Validation of a Comprehensive Multivariate Dosimetric Model for Predicting Late Genitourinary Toxicity Following Prostate Cancer Stereotactic Body Radiotherapy.
Valle LF; Ruan D; Dang A; Levin-Epstein RG; Patel AP; Weidhaas JB; Nickols NG; Lee PP; Low DA; Qi XS; King CR; Steinberg ML; Kupelian PA; Cao M; Kishan AU
Front Oncol; 2020; 10():786. PubMed ID: 32509582
[No Abstract] [Full Text] [Related]
12. Dosimetric benefits of hemigland stereotactic body radiotherapy for prostate cancer: implications for focal therapy.
Kishan AU; Park SJ; King CR; Roberts K; Kupelian PA; Steinberg ML; Kamrava M
Br J Radiol; 2015; 88(1056):20150658. PubMed ID: 26463234
[TBL] [Abstract][Full Text] [Related]
13. A dosimetric comparison of ultra-hypofractionated passively scattered proton radiotherapy and stereotactic body radiotherapy (SBRT) in the definitive treatment of localized prostate cancer.
Kole TP; Nichols RC; Lei S; Wu B; Huh SN; Morris CG; Lee S; Tong M; Mendenhall NP; Dritschilo A; Collins SP
Acta Oncol; 2015 Jun; 54(6):825-31. PubMed ID: 25227898
[TBL] [Abstract][Full Text] [Related]
14. A novel model to correlate hydrogel spacer placement, perirectal space creation, and rectum dosimetry in prostate stereotactic body radiotherapy.
Hwang ME; Black PJ; Elliston CD; Wolthuis BA; Smith DR; Wu CC; Wenske S; Deutsch I
Radiat Oncol; 2018 Oct; 13(1):192. PubMed ID: 30285812
[TBL] [Abstract][Full Text] [Related]
15. Late urinary toxicity modeling after stereotactic body radiotherapy (SBRT) in the definitive treatment of localized prostate cancer.
Kole TP; Tong M; Wu B; Lei S; Obayomi-Davies O; Chen LN; Suy S; Dritschilo A; Yorke E; Collins SP
Acta Oncol; 2016; 55(1):52-8. PubMed ID: 25972264
[TBL] [Abstract][Full Text] [Related]
16. A treatment planning study comparing IMRT techniques and cyber knife for stereotactic body radiotherapy of low-risk prostate carcinoma.
Scobioala S; Kittel C; Elsayad K; Kroeger K; Oertel M; Samhouri L; Haverkamp U; Eich HT
Radiat Oncol; 2019 Aug; 14(1):143. PubMed ID: 31399115
[TBL] [Abstract][Full Text] [Related]
17. Interfraction Anatomical Variability Can Lead to Significantly Increased Rectal Dose for Patients Undergoing Stereotactic Body Radiotherapy for Prostate Cancer.
Wahl M; Descovich M; Shugard E; Pinnaduwage D; Sudhyadhom A; Chang A; Roach M; Gottschalk A; Chen J
Technol Cancer Res Treat; 2017 Apr; 16(2):178-187. PubMed ID: 27199276
[TBL] [Abstract][Full Text] [Related]
18. Plan quality improvement by DVH sharing and planner's experience: Results of a SBRT multicentric planning study on prostate.
Villaggi E; Hernandez V; Fusella M; Moretti E; Russo S; Vaccara EML; Nardiello B; Esposito M; Saez J; Cilla S; Marino C; Stasi M; Mancosu P
Phys Med; 2019 Jun; 62():73-82. PubMed ID: 31153401
[TBL] [Abstract][Full Text] [Related]
19. Dosimetric Predictors of Toxicity after Prostate Stereotactic Body Radiotherapy: A Single-Institutional Experience of 145 Patients.
Fujii K; Nakano M; Kawakami S; Tanaka Y; Kainuma T; Tsumura H; Tabata KI; Satoh T; Iwamura M; Ishiyama H
Curr Oncol; 2023 May; 30(5):5062-5071. PubMed ID: 37232841
[TBL] [Abstract][Full Text] [Related]
20. Impact of Interfractional Bladder and Trigone Displacement and Deformation on Radiation Exposure and Subsequent Acute Genitourinary Toxicity: A Post Hoc Analysis of Patients Treated with Magnetic Resonance Imaging-Guided Prostate Stereotactic Body Radiation Therapy in a Phase 3 Randomized Trial.
Neilsen BK; Ma TM; Akingbemi WO; Neylon J; Casado MC; Sharma S; Sheng K; Ruan D; Low DA; Yang Y; Valle LF; Steinberg ML; Lamb JM; Cao M; Kishan AU
Int J Radiat Oncol Biol Phys; 2024 Mar; 118(4):986-997. PubMed ID: 37871887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
